


Market Data	
52-week high/low	SAR 5.92 / 4.10
Market Cap	SAR 5,178 mln
Shares Outstanding	1,143 mln
Free-float	26.54%
12-month ADTV	844,534
Bloomberg Code	BINDAWOO AB



Growing Ecosystem Seeks Synergies with Grocery Business

August 13, 2026

Upside to Target Price (0.7%)
 Expected Dividend Yield 1.8%
 Expected Total Return 1.1%

Rating Neutral
 Last Price SAR 4.53
 12-mth target SAR 4.50

BDH	2Q2026	2Q2025	Y/Y	1Q2026	Q/Q	RC Estimate
Sales	1,643	1,474	11%	1,811	(9%)	1,555
Gross Profit	576	533	8%	580	(1%)	498
Gross Margins	35%	36%		32%		32%
Operating Profit	101	80	26%	110	(8%)	82
Net Profit	50	52	(4%)	70	(29%)	50

(All figures are in SAR mln)

- BDH reported 2Q26 revenue of SAR 1,643 mln (+11% Y/Y, -9% Q/Q), slightly above our SAR 1,555 mln estimate, and gross profit of SAR 576 mln (+8% Y/Y, -1% Q/Q), materially above our SAR 498 mln, driven by gross margin of 35% being higher than our 32% forecast. Operating profit of SAR 101 mln (+26% Y/Y, -8% Q/Q) was also above our SAR 82 mln forecast. Net profit (attributable to shareholders) of SAR 50 mln (-4% Y/Y, -29% Q/Q) matched our SAR 50 mln estimate. We also note that growth was carried by grocery expansion, a full period of Toy Triangle and one month of Vaza Foods.
- Consolidated net profit rose +5.3% Y/Y to SAR 53.2 mln, but the attributable figure fell -4% to SAR 50 mln: non-controlling interests took SAR 3.6 mln in 2Q26 versus SAR (1.3) mln in 2Q25, an increase of roughly SAR 5 mln. Below the operating line, costs absorbed SAR 48 mln versus SAR 30 mln in 2Q25, driven by lease liabilities, acquisition financing and lower finance income. We would remind investors that the +306 bps Q/Q gross margin increase was supported by the recognition of pharmacy rebates and target incentives.
- The operating story is intact — 103 grocery and 209 pharmacy stores, Vaza Foods consolidated from 1 June, Wonder Bakery expected in 3Q26 and the first Riyadh store opened in July 2026 — but earnings attributable to shareholders were flat over the 1H26 vs. 1H25 periods, at SAR 119.7 mln (+0.6% Y/Y), while the acquisition program is debt-funded and the minority share is rising. Wasfaty modifications continue to weigh on pharmacy revenue as well, consistent with what we observe across our pharmacy retail coverage. We remain Neutral and hold our target price while we wait for the financials to review the net debt position.

Brennan Eatough
 brennan.eatough@riyadcapital.com
 +966-11-203-6808

■ Stock Rating

Buy	Neutral	Sell	Not Rated
Expected Total Return Greater than +15%	Expected Total Return between -15% and +15%	Expected Total Return less than -15%	Under Review/Restricted

The expected percentage returns are indicative, stock recommendations also incorporate relevant qualitative factors

For any feedback on our reports, please contact research@riyadcapital.com

Riyad Capital is a Saudi closed joint stock company with paid-up capital of SAR 500 million. Licensed by the Saudi Arabian Capital Market Authority (No. 07070-37). Commercial Registration No. 1010239234. Head Office: 3128 Financial Boulevard, 6671 Al Aqeeq Dist., Riyadh 13519, Kingdom of Saudi Arabia. Ph: 920012299.

The information in this report was compiled in good faith from various public sources believed to be reliable. Whilst all reasonable care has been taken to ensure that the facts stated in this report are accurate and that the forecasts, opinions and expectations contained herein are fair and reasonable. Riyad Capital makes no representations or warranties whatsoever as to the accuracy of the data and information provided and, in particular, Riyad Capital does not represent that the information in this report is complete or free from any error. This report is not, and is not to be construed as, an offer to sell or solicitation of an offer to buy any financial securities. Accordingly, no reliance should be placed on the accuracy, fairness or completeness of the information contained in this report. Riyad Capital accepts no liability whatsoever for any loss arising from any use of this report or its contents, and neither Riyad Capital nor any of its respective directors, officers or employees, shall be in any way responsible for the contents hereof. Riyad Capital or its employees or any of its affiliates or clients may have a financial interest in securities or other assets referred to in this report. Opinions, forecasts or projections contained in this report represent Riyad Capital's current opinions or judgment as at the date of this report only and are therefore subject to change without notice. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or projections which represent only one possible outcome. Further, such opinions, forecasts or projections are subject to certain risks, uncertainties and assumptions that have not been verified and future actual results or events could differ materially. The value of, or income from, any investments referred to in this report may fluctuate and/or be affected by changes. Past performance is not necessarily an indicative of future performance. Accordingly, investors may receive back less than originally invested amount. This report provides information of a general nature and does not address the circumstances, objectives, and risk tolerance of any particular investor. Therefore, it is not intended to provide personal investment advice and does not take into account the reader's financial situation or any specific investment objectives or particular needs which the reader may have. Before making an investment decision the reader should seek advice from an independent financial, legal, tax and/or other required advisers due to the investment in such kind of securities may not be suitable for all recipients. This research report might not be reproduced, nor distributed in whole or in part, and all information, opinions, forecasts and projections contained in it are protected by the copyright rules and regulations.